Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ceribell (CBLL) Capital Expenditures (2023 - 2026)

Ceribell posted quarterly Capital Expenditures of $125000.0 for Q1 2026, down 15.54% year-on-year from $148000.0 in Q1 2025, and down 30.17% on a QoQ basis from $179000.0 in Q4 2025.

Ceribell (CBLL) has 4 years of Capital Expenditures data on file, last reported at $125000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Capital Expenditures fell 15.54% year-over-year to $125000.0; the trailing twelve-month figure through Mar 2026 stood at $744000.0 (down 46.59% YoY), and the FY2025 full-year result was $767000.0, down 42.76% from the prior year.
  • Capital Expenditures for Q1 2026 stood at $125000.0, down from $179000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $567000.0 in Q3 2024 and bottomed at $71000.0 in Q2 2025.
  • The 4-year median for Capital Expenditures is $250000.0 (2024), against an average of $270900.0.
  • Peak annual rise in Capital Expenditures reached 55.79% in 2025, while the deepest fall reached 77.88% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $477000.0 in 2023, then slipped by 25.16% to $357000.0 in 2024, then sank by 49.86% to $179000.0 in 2025, then slumped by 30.17% to $125000.0 in 2026.
  • The last three Capital Expenditures figures came in at $125000.0 (Q1 2026), $179000.0 (Q4 2025), and $369000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 399.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 166.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 444.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 177.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 64.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -85.46 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 76.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 86.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 90.20 Mn
10 Ceribell 666.26 Mn 525.07 Mn 23.12 Mn 125,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 125,000.00
Mar 31, 2026 125,000.00
Dec 31, 2025 179,000.00
Dec 31, 2025 179,000.00
Sep 30, 2025 369,000.00
Sep 30, 2025 369,000.00
Jun 30, 2025 71,000.00
Jun 30, 2025 71,000.00
Mar 31, 2025 148,000.00
Mar 31, 2025 148,000.00
Dec 31, 2024 357,000.00
Dec 31, 2024 357,000.00
Sep 30, 2024 567,000.00
Sep 30, 2024 567,000.00
Jun 30, 2024 321,000.00
Jun 30, 2024 321,000.00
Mar 31, 2024 95,000.00
Mar 31, 2024 95,000.00
Dec 31, 2023 477,000.00
Dec 31, 2023 477,000.00